🇺🇸 Calcichew D3 in United States

2,225 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 2,225

Most-reported reactions

1. Diarrhoea — 249 reports (11.19%)
2. Dyspnoea — 248 reports (11.15%)
3. Malaise — 246 reports (11.06%)
4. Nausea — 234 reports (10.52%)
5. Fall — 223 reports (10.02%)
6. Vomiting — 218 reports (9.8%)
7. Acute Kidney Injury — 215 reports (9.66%)
8. Fatigue — 211 reports (9.48%)
9. Hyponatraemia — 202 reports (9.08%)
10. Dizziness — 179 reports (8.04%)

Source database →

Frequently asked questions

Is Calcichew D3 approved in United States?

Calcichew D3 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Calcichew D3 in United States?

Takeda is the originator. The local marketing authorisation holder may differ — check the official source linked above.